<scp>TCL</scp>1 expression predicts overall survival in patients with mantle cell lymphoma

Shin, Su‐Jin; Roh, Jin; Jeong, Hee; Choi, Yoo Duk; Kim, Jin Man; Min, Soo Kee; Kim, Ji Eun; Eom, Dae-Woon; Lee, Hojung; Kim, Hyun Jung; Yoon, Dok Hyun; Suh, Cheolwon; Huh, Jooryung

doi:10.1111/ejh.12539

Cited by 9 publications

(5 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For Ki-67, the index was defined as the percentage of Ki-67-positive cells among all the cells of the TMA section. Slides were scanned and digitalized using a Pannoramic MIDI (3DHISTECH, Ltd., Budapest, Hungary) and analyzed using a Pannoramic Viewer v. 1.15.3 and NuclearQuant application for PV v.2.0.0.46136, both manufactured by 3DHISTECH (18).…”

Section: Methodsmentioning

confidence: 99%

SIRT3 is correlated with the malignancy of non-small cell lung cancer

Xiong

Wang

Zhao

et al. 2017

International Journal of Oncology

View full text Add to dashboard Cite

The mitochondrial deacetylase SIRT3 plays a pivotal role in the initiation and the progression of certain cancers acting as an oncogene. However, in others it acts anti-oncogenically. Its conflicting action is possibly due to the different key proteins it modifies depending on the context of active intracellular signaling pathways in different cancers. SIRT3 is thus a novel target for preventing and treating cancer. In the present study, we explored the function of SIRT3 in non-small cell lung cancer (NSCLC) with the aim of elucidating the underlying mechanisms. We first determined the SIRT3 expression levels by real-time PCR, western blotting and immunohistochemistry on tissue microarrays of paired samples of NSCLC tissue and adjacent normal tissue from 70 patients with associated clinicopathological data. Levels of SIRT3 protein and mRNA were significantly increased in NSCLC tissue, compared with normal tissue (P<0.05). Expression of SIRT3 in NSCLC positively correlated with that of malignant biomarker Ki-67 (P<0.05) and oncogene p-Akt (P<0.05). Patients with higher SIRT3 expression had a shorter overall survival duration (P<0.05). NSCLC tissue of squamous cell carcinoma type had higher SIRT3 expression compared with other types (P<0.05). Furthermore, among the clinicopathological variables examined, SIRT3 expression was correlated only with pathological type (P<0.05). In NSCLC cell lines, we found that downregulation of SIRT3 by siRNA decreased the activation of Akt, and that SIRT3 overexpression caused the activation of Akt. In addition, in a NSCLC cell line, SIRT3 was able to co-immunoprecipitate Akt and co-located with Akt, suggesting that SIRT3 regulates the activation of Akt through post-transcriptional modification. Our findings suggest that SIRT3 promotes the malignancy of NSCLC, showing an oncogenic preference towards squamous cell carcinoma, and that could represent a novel target for treatment.

show abstract

Section: Methodsmentioning

confidence: 99%

SIRT3 is correlated with the malignancy of non-small cell lung cancer

Xiong

Wang

Zhao

et al. 2017

International Journal of Oncology

View full text Add to dashboard Cite

show abstract

“…In MCLs, our assay retrieved the expected CCND1high, CD5high, and BCL2high phenotype, together with the expected downregulation of CD10 and CD23. Interestingly, TCL1A and CCDC50, both of which are associated with survival in patients with this pathology 18,19 , and the B-cell chemokine receptor CXCR5, which is involved in dissemination 20 , were overexpressed in these tumors compared to other small B-cell NHLs. Finally, the MZL group showed the expected CD5neg, CD10neg, CD23neg phenotype, together with high expression of CD138 and low expression of Ki67.…”

Section: Small B-cell Lymphoma Classificationmentioning

confidence: 96%

Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma

et al. 2020

View full text Add to dashboard Cite

Non-Hodgkin B-cell lymphomas (B-NHLs) are a highly heterogeneous group of mature B-cell malignancies. Their classification thus requires skillful evaluation by expert hematopathologists, but the risk of error remains higher in these tumors than in many other areas of pathology. To facilitate diagnosis, we have thus developed a gene expression assay able to discriminate the seven most frequent B-cell NHL categories. This assay relies on the combination of ligation-dependent RT-PCR and next-generation sequencing, and addresses the expression of more than 130 genetic markers. It was designed to retrieve the main gene expression signatures of B-NHL cells and their microenvironment. The classification is handled by a random forest algorithm which we trained and validated on a large cohort of more than 400 annotated cases of different histology. Its clinical relevance was verified through its capacity to prevent important misclassification in low grade lymphomas and to retrieve clinically important characteristics in high grade lymphomas including the cell-of-origin signatures and the MYC and BCL2 expression levels. This accurate pan-B-NHL predictor, which allows a systematic evaluation of numerous diagnostic and prognostic markers, could thus be proposed as a complement to conventional histology to guide the management of patients and facilitate their stratification into clinical trials.

show abstract

“…Other biomarkers and characteristic features of MCL that have shown prognostic significance for poor outcome include presence of blastoid or pleomorphic morphologic characteristics and high proliferation index at the time of diagnosis or after intense therapy [79]. In addition, high expression of eukaryotic initiation factor 4E, Myc and SOX11 overexpression, low TCL1 expression, TP53 alterations, lack of hypermutated heavy chain immunoglobulin variable regions, presence of higher absolute levels of monocytes, beta-2 microglobulin, monoclonal and polyclonal immunoglobulin free light chain, IL-2Rα, IL-8, and MIP-1β in the serum have been correlated with poor prognosis and inferior outcome [51, 69, 80–85]. CD3(+), CD8(+), and particularly CD4(+) T cells, if present in high numbers, are characteristic of the indolent form of MCL; a high CD4:CD8 ratio correlates independently with longer OS [86].…”

Section: Prognostic Markers For MCLmentioning

confidence: 99%

Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents

et al. 2016

View full text Add to dashboard Cite

Despite advances in the development of clinical agents for treating Mantle Cell Lymphoma (MCL), treatment of MCL remains a challenge due to complexity and frequent relapse associated with MCL. The incorporation of conventional and novel diagnostic approaches such as genomic sequencing have helped improve understanding of the pathogenesis of MCL, and have led to development of specific agents targeting signaling pathways that have recently been shown to be involved in MCL. In this review, we first provide a general overview of MCL and then discuss about the role of biomarkers in the pathogenesis, diagnosis, prognosis, and treatment for MCL. We attempt to discuss major biomarkers for MCL and highlight published and ongoing clinical trials in an effort to evaluate the dominant signaling pathways as drugable targets for treating MCL so as to determine the potential combination of drugs for both untreated and relapse/refractory cases. Our analysis indicates that incorporation of biomarkers is crucial for patient stratification and improve diagnosis and predictability of disease outcome thus help us in designing future precision therapies. The evidence indicates that a combination of conventional chemotherapeutic agents and novel drugs designed to target specific dysregulated signaling pathways can provide the effective therapeutic options for both untreated and relapse/refractory MCL.

show abstract

TCL1 expression predicts overall survival in patients with mantle cell lymphoma

Abstract: Our study suggests that TCL1 expression profile may have a role in the prediction of overall outcome in patient with MCL and call for prospective studies.

Cited by 9 publications

References 42 publications

SIRT3 is correlated with the malignancy of non-small cell lung cancer

SIRT3 is correlated with the malignancy of non-small cell lung cancer

Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma

Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents

Contact Info

Product

Resources

About